High-risk metastatic urothelial cancer: Chances for cure?

Current Opinion in Urology

Volumn 12, Issue 5, 2002, Pages 441-448

  Calabrò, Fabio ^a   Sternberg, Cora N ^a  

^a Vincenzo Pansadoro Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; METHOTREXATE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; VINBLASTINE;

ANEMIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; METASTASIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

CARCINOMA, TRANSITIONAL CELL; HUMANS; RISK ASSESSMENT; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0036739839     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200209000-00013     Document Type: Review

References (67)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33-64.
2. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992; 10:1066-1073.
3. Geller NL, Sternberg CN, Penenberg D, et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991; 67:1525-1531.
4. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-2569.
5. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17:3173-3181.
6. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 1989; 64:2446-2458.
7. Logothetis CJ, Dexeus F, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol 1990; 8:1050-1055.
8. McCaffrey JA, Dodd PM, Herr H, et al. Nonbladder primary site of transitional cell carcinoma (TCC) does not affect probability of response to M-VAC or survival [Abstract]. Proc Am Soc Clin Oncol 1998; 17:337a.
9. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989; 142:289-292.
10. Sternberg C, de Mulder P, van Oosterom AT, et al. Escalated M-VAC chemotherapy and recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 1993; 4:403-407.
11. Loehrer PJ, Elson P, Dreicer R, et al. A phase I-II study: escalated dosages of methotrexate (M), vinblastine (V), doxorubicin (A), and cisplatin (C) plus rhG-CSF in advanced urothelial carcinoma: an ECOG trial [Abstract]. Proc Am Soc Clin Oncol 1992; 11:201.
12. Logothetis C, Finn L, Amato R, et al. Escalated (ESC) MVAC +/- rhGM-CSF (Schering-Plough) in metastatic transitional cell carcinoma (TCC): preliminary results of a randomized trial [Abstract]. Proc Am Soc Clin Oncol 1992; 11:202.
13. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1992; 11:414-420.
14. Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 2001; 19:2638-2646.
15. Dodd PM, McCaffrey JA, Mazumdar M, et al. Evaluation of drug delivery and survival impact of close-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer Invest 2000; 18:626-634.
16. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol 2000; 27 (Suppl 2):31-39.
17. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998; 34:1208-1212.
18. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441-3445.
19. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5:182-184.
20. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15:3394-3398.
21. Gebbia V, Testa A, Borsellino N, et al. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999; 150:11-15.
22. Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264-2270.
23. Papamichael D, Gallagher CJ, Oliver RT, et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75:606-607.
24. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940.
25. de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer: results of a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998; 78:1342-1345.
26. Dimopoulos MA, Deliveliotis C, Moulopoulos LA, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 1998; 52:56-60.
27. McCaffrey J, Dodd PM, Hilton S, et al. Ifosfamide and paclitaxel and cisplatin (ITP) chemotherapy for patients (Pts) with unresectable or metastatic transitional cell carcinoma (TCC) [Abstract]. Proc Am Soc Clin Oncol 1999; 18:329a.
28. von der Maase H. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer. Eur J Cancer 2000; 36 (Suppl 2):13-16.
29. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-1927.
30. Lorusso V, Manzione L, De Vita F, et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000; 164:53-56.
31. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Trials Group. J Clin Oncol 1999; 17:2876-2881.
32. von der Maase H, Andersen L, Crino L, et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999; 10:1461-1465.
33. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
34. Rothenberg ML, Sharm A, Weis GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 9:733-738.
35. Sternberg CN, Calabrò F, Pizzocaro G, et al. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993-2998.
36. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies [Abstract]. Proc Annu Meet Am Soc Clin Oncol 2002; 21:150b.
37. Fechner GH, Siener R, Reimann M, et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma [Abstract]. J Urol 2002; 167 (4 Suppl);284.
38. Kaufmann DS, Carducci MA, Kuzel T, et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC) [Abstract]. Proc Annu Meet Am Soc Clin Oncol 2002; 21:192a.
39. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19:3018-3024.
40. Kaufman DS, Stadler WM, Carducci MA, et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2W): a multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC) [Abstract]. Proc Am Soc Clin Oncol 2000; 19:341a.
41. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrextae, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 1997; 15:2449-2455.
42. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18:3247-3255.
43. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. J Clin Oncol (in press).
44. Hussain M, Vaishampayan U, Du W, et al. Combination paciitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19:2527-2533.
45. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 2000; 18:840-846.
46. Maluf FC, Hilton S, Nanus DM, et al. Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel and cisplatin (ITP) chemotherapy (AG-ITP) in patients (Pts) with metastatic or locally advanced transitional cell carcinoma of the urothelium (TCC) [Abstract]. Proc Am Soc Clin Oncol 2000; 19:342a.
47. Droz JP, Mottet N, Prapotrich D, et al. Phase II study of taxol (paclitaxel) and carboplatin in patients with advanced transitional cell carcinoma of the urothelium: preliminary results [Abstract]. Proc Am Soc Clin Oncol 1998; 17:316a.
48. Meyers FJ, Edelman MJ, Houston J, Lauder I. Phase I/II trial of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma [Abstract]. Proc Am Soc Clin Oncol 1998; 17:317a.
49. Pycha A, Grbovic M, Posch B, et al. 2-years experience with paclitaxel/carboplatin as first line therapy in metastatic bladder cancer [Abstract]. J Urol 1999; 263:1015.
50. Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998; 16:1844-1848.
51. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000; 18:2537-2544.
52. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998; 16:255-260.
53. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur J Cancer 2001; 37:2212-2215.
54. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59:24-27.
55. Lladò A, Bellmunt G, Kaiser G, et al. A dose finding study of carboplatin with fixed doses of gemcitabine in 'unfit' patients with advanced bladder cancer [Abstract]. Proc Am Soc Clin Oncol 2000; 19:344a.
56. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001; 165:811-814.
57. Siefker-Radtke AO, Walsh GL, Swanson DA, et al. Is there a role for surgery in the management of metastatic urothelial cancer? An update of the M.D. Anderson experience [Abstract]. J Urol 2002; 167 (4 Suppl):283.
58. Sweeney P, Millikan RE, Wood CG, Pettaway CA. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic transitional cell carcinoma (TCC) of the bladder [Abstract]? J Urol 2002; 167 (4 Suppl):283.
59. Otto T, Krege S, Suhr J, Rubben H. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 2001; 57:55-59.
60. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001; 8:9-15.
61. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
62. Jimenez RE, Hussain M, Bianco FJJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7:2440-2447.
63. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001; 12 (Suppl 1):S81-S87.
64. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28 (4 Suppl 15):67-70.
65. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997; 385:123-125.
66. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381:713-716.
67. Kielb SJ, Shah NL, Rubin MA, Sanda MG. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol 2001; 166:482-487.